Spotlight On... Glaxo socks more cash into immunotherapy bet; Justice wants a bankruptcy trustee to take over KaloBios; CVS to roll out naloxone OTC in Ohio; and more...

Last year, GlaxoSmithKline ($GSK) traded away most of its cancer assets to Novartis ($NVS) in exchange for the majority of the Swiss drugmaker's vaccines portfolio. But it's not out of the area altogether, and now, it's sweetening a deal with oncology partner Adaptimmune. Glaxo has promised more cash to speed up development of a promising treatment for soft tissue sarcoma, pledging to fund pivotal trials for the immunotherapy. Read more from FierceBiotech

@FiercePharma: Roche expects April price cut for Avastin in Japan where Tamiflu sales also hit. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says. Article | Follow @CarlyHFierce

> The controversial and bankrupt California-based biotech KaloBios Pharmaceuticals, briefly run by "pharma bro" CEO Martin Shkreli, needs to be taken over by an independent trustee, a Justice Department unit says. Report

> CVS Health ($CVS) says it will make the opioid antidote naloxone available over the counter in Ohio to help reduce overdose deaths. Report

> Allergy specialist Stallergenes Greer, based in London, has restarted production at a plant in France where operations had been suspended. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: IBM Watson, AHA and Welltok to develop workplace heart health program. Article | Follow @FierceMedDev

@VarunSaxena2: Updated w analyst info: Stryker to buy disposable device maker for $2.8B to reduce hospital-acquired infections. Report | Follow @VarunSaxena2

@EmilyWFierce: Roche sees no 'short term' pricing pressure for company's cancer drugs: Reuters. FiercePharma story | Follow @EmilyWFierce

> Med tech shops around for cost-cutting deals amid increased demand from hospitals. Report

> At Baxter, Covidien's Almeida looks to cut costs, fuel innovation and do smaller acquisitions. Story

> Swiss contract manufacturer diversifies into med tech via $895M acquisition of Creganna Medical. Article

Biotech News

@FierceBiotech: Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund. Report | Follow @FierceBiotech

@JohnCFierce: Trending: Will Zika frenzy fuel an overnight vaccine R&D miracle? Don't bet on it. More | Follow @JohnCFierce

@DamianFierce: the only thing I miss about working at a newspaper is election night pizza. | Follow @DamianFierce

> GlaxoSmithKline up-sizes its bet on Adaptimmune, racing forward with a cancer immunotherapy. Story

> Sanofi chops into R&D operations in France in latest retrenchment. Article

> Glaxo, Atlas syndicate bankrolls Spero's drive into the clinic with $30M round. Report

Pharma Manufacturing News

> Troubled Sun Pharma manages U.S. launch of copy of blockbuster Gleevec. Report

> Teva U.K. plant cuts 80 jobs as drugmaker looks for higher skilled workers. News

> CDMO Vetter finishes IT upgrade at German facility. Story

> FDA hands Wockhardt and Ipca more disappointing news. Article

> Allergan CEO suggests expanded Texas plant may be in store for more jobs. More

Drug Delivery News

> Mercator launches microinfusion catheter trial for below-the-knee ischemia. More

> New CRISPR/Cas9 delivery method could offer a clinical pathway. Report

> FDA approves the first extended-release orally disintegrating tablet for ADHD. Item

> Dr. Reddy's wins approval for injectable generic to treat migraines. Story

> Aprecia completes $35M financing to support launch of the first 3-D printed medication. Article

Pharma Asia News

> BMS details new Japan hit to hep C sales. Item

> India's Sun Pharmaceutical meets Feb. 1 deadline for U.S. imatinib launch. More

> Management moves to take Nasdaq-listed Sinovac Biotech private in growing trend. Report

> China's Qiming's fifth U.S. dollar venture fund clocks in at $648 million in commitments. Story

> Amgen says it's awaiting reimbursement details after Japan Repatha nod. Article

And Finally... The internet in your head? The brain's capacity is 10 times greater than previously thought, a study found. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…